Mensen vragen ons vaak wat Angelman nou precies inhoud en of er wat tegen te doen is. De tekst hier onder geeft een duidelijk beeld van wat het Angelman syndroom is en hoever de wetenschap al is.
How close are we to a Cure?(bron:curegarret.com)
Understanding the Science behind Angelman Syndrome will help illustrate how close we are to a cure.Angelman Syndrome is unique in many ways.
Angelman Syndrome is unique because 
it is caused by loss of function of a single gene rather than many genes
 and the gene is known – UBE3A. UBE3A is located on Chromosome 15. Each 
human being inherits a copy of Chromosome 15 from each of their parents.
 That means we each have a pair of UBE3A genes – a paternal copy from 
our father and a maternal copy from our mother.
Scientists
 have a solid understanding of the role that UBE3A plays in the body. 
The UBE3A gene produces Ubiquitin-protein ligase E3A which is essential 
to learning. In the brain, this enzyme allows for “neuron plasticity” 
which means it allows for neurons to bend and link together to form the 
pathways essential in learning. Without Ubiquitin-protein ligase E3A, 
one cannot learn.
The gene UBE3A is itself quite unique
 because of “genomic imprinting.” In every person, the paternal copy of 
UBE3A is silent – only the maternal copy is functional and actively used
 to produce Ubiquitin-protein ligase E3A. In children with Angelman 
Syndrome the maternal copy has either been mutated or is missing (via 
deletion or UPD). Even though their paternal copy is likely healthy, it 
is silent.
Genomic Imprinting Example
 In this illustration you can see that both mice have a mutated gene 
which causes dwarfism. However, only the bottom mouse suffers dwarfism 
because, due to imprinting, in this case the mutated gene must be on the
 paternal copy to have an effect.
 In this illustration you can see that both mice have a mutated gene 
which causes dwarfism. However, only the bottom mouse suffers dwarfism 
because, due to imprinting, in this case the mutated gene must be on the
 paternal copy to have an effect.
The
 implications of genomic imprinting are perhaps the most important. On 
one hand, it is due to this uniqueness in UBE3A that a child would even 
have Angelman Syndrome, however, on the other hand, it lends itself to a
 possible cure. Since every child carries a silent healthy paternal copy
 of UBE3A, unsilencing that gene would allow the brain to produce 
Ubiquitin-protein ligase E3A.
Scientists
 have developed an Angelman Syndrome mouse model. These mice lack the 
maternal UBE3A gene and thus, lack Ubiquitin-protein ligase E3A. Their 
behavior and physiological conditions are quite similar to conditions in
 human Angelman Syndrome individuals. Scientists have shown that 
reintroduction of Ubiquitin-protein ligase E3A into an Angelman Syndrome
 mouse model causes reversal of symptoms – the mice are able to learn 
and develop as a typical mouse would.
This
 is extremely important because it shows us that not only is the 
“damage” not permanent, but a cure could potentially reverse the 
debilitating effects of Angelman Syndrome. Garrett could learn to talk 
and develop as a typical person – living a fully functional life! This 
is such an amazing thing to hope for and that is why it is so important 
that we push for a cure as soon as possible!
The 
next step is to understand how the paternal copy is being silenced so 
that we can unsilence it. Just within the last few years there have been
 major advances in this area. Scientists now understand that the 
paternal copy is being “epigenetically silenced.” Essentially, there is 
so much activity on the active genes just upstream of UBE3A on the 
paternal chromosome 15 that the site is simply “too busy” for the UBE3A 
gene to be expressed. This is why you actually do see some very low 
levels of Ubiquitin-protein ligase E3A being expressed in Angelman 
Syndrome individuals.
A
 good way to look at this scenario is that our DNA is extremely active –
 there is a constant flow of delivery trucks (transcription enzymes) 
attaching to their docking station and copying genes. The copy they make
 becomes a protein which is used in the human body. We need the UBE3A 
gene to produce its protein – Ubiquitin-protein ligase E3A – but there 
are just too many trucks going in and out of the genes nearby! They are 
incidentally blocking our much needed truck from picking up its cargo!
Knowing
 this, a possible solution is to custom build a protein which will bind 
to those genes just upstream of UBE3A, preventing all those trucks from 
going to work there. This would allow our truck to bind and allow for 
UBE3A expression. Just this type of solution is now being shown to work 
at UCDavis and other research institutions – it is absolutely cutting 
edge science.
Scientists now have a variety of tools at their disposal to make this possible:
I. Zinc Finger Proteins, TARs, and CRISPr are all ways to make “custom fit” proteins with affinity to long specific stretches of DNA.
II. Delivery proteins have been created which can “carry” a desired protein from a site of injection to the brain and into the neuron.
III. Tracking proteins allow for real time imaging of the spread of the medicine throughout the cells of the body.
IV. Measurement of Ubiquitin-protein ligase E3A enzyme allows scientists to confirm successful expression of the silenced gene.
V. Behavioral scientists who specialize in mice, rat, pig and other animal behaviors can evaluate changes and determine the theoretical implications in humans.
I. Zinc Finger Proteins, TARs, and CRISPr are all ways to make “custom fit” proteins with affinity to long specific stretches of DNA.
II. Delivery proteins have been created which can “carry” a desired protein from a site of injection to the brain and into the neuron.
III. Tracking proteins allow for real time imaging of the spread of the medicine throughout the cells of the body.
IV. Measurement of Ubiquitin-protein ligase E3A enzyme allows scientists to confirm successful expression of the silenced gene.
V. Behavioral scientists who specialize in mice, rat, pig and other animal behaviors can evaluate changes and determine the theoretical implications in humans.
The
 above formula for a cure is very quickly becoming a reality. Scientists
 have shown this process to be successful in mice already. Angelman 
Syndrome model mice were injected with a protein with the goal of 
blocking the nearby genes and unsilencing the paternal UBE3A gene. It 
worked! Ubiquitin-protein ligase E3A was confirmed to be produced by the
 cells at near normal levels and behavior improved in some areas!
There
 are still many steps that need to be taken – further trials in higher 
order species, analysis of findings, evaluation of possible side effects
 (short and long term), and hopefully the development of more feasible 
delivery systems are just the first of these steps.
Scientists
 are confident that a cure will be here soon and that gives us reason to
 hope. But we desperately need more funding to make it happen! Please 
help us spread the word to make this possible! Every voice and every 
dollar gets us closer to a cure for Angelman Syndrome!
 
Geen opmerkingen:
Een reactie posten